Table 1.
Clinicopathologic variables of the patient cohort
| Variable | Number of patients | Percentage (%) |
|---|---|---|
| Age | ||
| ≤ 62 | 295 | 52.4 |
| > 62 | 268 | 47.6 |
| Histological subtypes | ||
| HGSC | 337 | 59.7 |
| Mucinous carcinoma | 60 | 10.6 |
| Endometrioid carcinoma | 68 | 12.1 |
| CCC | 53 | 9.4 |
| LGSC | 30 | 5.3 |
| SBOT | 15 | 2.7 |
| Grade | ||
| 1 | 48 | 8.5 |
| 2 | 90 | 16.0 |
| 3 | 425 | 75.5 |
| Stage | ||
| I | 203 | 36.7 |
| II | 64 | 11.6 |
| III | 245 | 44.3 |
| IV | 41 | 7.4 |
| Residual disease | ||
| No residual tumour | 311 | 62.2 |
| Residual tumour (< 2 cm) | 58 | 11.6 |
| Residual tumour (> 2 cm) | 131 | 26.2 |
| Adjuvant therapy | ||
| Pt-based chemotherapy | 357 | 63.3 |
| Non-platinum-based chemotherapy | 6 | 1.1 |
| No chemotherapy | 80 | 14.2 |
| Information not available | 121 | 21.5 |
| Response to chemotherapy | ||
| Refractory and resistance | 66 | 17.7 |
| Sensitivity | 307 | 82.3 |
| Progression status | ||
| No recurrence | 137 | 32.9 |
| Recurred | 280 | 67.1 |
| Survival status | ||
| Living | 234 | 42.0 |
| Deceased | 323 | 58.0 |